Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 Jun 17.
Published in final edited form as: Dev Cell. 2019 Jun 17;49(6):827–828. doi: 10.1016/j.devcel.2019.05.039

Single-Cell Analyses Confirm the Critical Role of LRP6 for Wnt Signaling in APC-Deficient Cells

Carly R Cabel 1, Elaheh Alizadeh 1, David J Robbins 2, Yashi Ahmed 3,*, Ethan Lee 4,*, Curtis A Thorne 1,*
PMCID: PMC6613640  NIHMSID: NIHMS1039415  PMID: 31211991

The majority of colorectal cancers (CRCs) are initiated by constitutive activation of Wnt signaling resulting from truncation of the tumor suppressor adenomatous polyposis coli (APC) (Clevers and Nusse, 2012). APC promotes β-catenin turnover via its function within the destruction complex. In this traditional model, the Wnt receptor complex is dispensable for constitutive Wnt pathway activation and consequent CRC development following APC loss. Our published findings (Saito-Diaz et al., 2018) reveal an additional evolutionarily conserved function of APC: prevention of ligand-independent Wnt receptor complex signalosome formation. This novel APC function ensures receptor activation occurs only after Wnt stimulation. Thus, in our recently proposed model (Thorne et al., 2018), APC has two functions: (1) to promote β-catenin degradation (its traditional role) and(2) to prevent inappropriate receptor activation when Wnts are absent.

In this issue of Developmental Cell, Chen and He used CRISPR/Cas9 genome editing to generate cell lines in which APC and LRP6 and/or LRP5 were knocked out and failed to observe changes in β-catenin levels or Wnt reporter activity. They considered the possibility that compensation or adaptation, which are previously described phenomena (El-Brolosy and Stainier, 2017; Rossi et al., 2015), occurred in these cell lines as a result of the genetic deletions. To address this, the authors performed siRNA knockdown of LRP6 in APC-deficient cells but failed to observe decreased activity of a Wnt target gene reporter. Paradoxically, they observed increased Wnt reporter activity following LRP6 knockdown that they attributed to an LRP6 siRNA off-target effect. They concluded that APC loss results in Wnt signaling independent of LRP6/5, which is inconsistent with our newly proposed model. The implication was that other components of the Wnt receptor complex are also not necessary for the aberrant activation of Wnt signaling caused by loss of APC.

Genetic and biochemical instability of cancer cell lines leads to significant cell-to-cell heterogeneity (Ben-David et al., 2018; Liu et al., 2019). One explanation for our disparate results is that CRISPR/Cas9-mediated LRP5/6 knockout as performed by Chen and He resulted in compensatory genetic mechanisms that maintain elevated Wnt signaling over time in knockout clones. Although siRNA knockdown was utilized to rule out this possibility, β-catenin levels were not reported; thus a comparison of their data with our previous and current results cannot be made. We are unable to explain why Chen and He observed paradoxical enhancement of Wnt reporter activity upon knockdown of LRP6, but this apparently artifactual effect may have masked the requirement for LRP6 in APC-deficient cells. In addition, greater than 90% knockdown of a given component must be achieved to disrupt function of other signaling pathways (Krumins and Gilman, 2006). Thus, we routinely perform double siRNA transfections (12 h apart) to achieve efficient knockdown. As LRP6 levels following knockdown were not shown by Chen and He, the efficiency of LRP6 depletion in the various cell lines tested is not clear.

To rule out clonal idiosyncrasies or genetic compensation, we performed single-cell analyses of endogenous β-catenin levels in isogenic human colonic epithelial cell (HCEC) lines with defined oncogenic perturbations (Zhang et al., 2016). These immortalized cells are cytogenetically normal, retain the capacity to undergo multilineage epithelial cell differentiation, and exhibit a functional Wnt pathway (Roig et al., 2010). Using an LRP6-interfering oligonucleotide that contains a targeting sequence different from our previous study and from that used by Chen and He, we silenced LRP6 and measured nuclear and whole-cell β-catenin levels (Figure S1). Nuclear and total β-catenin levels were significantly reduced (Figures S1B and S1C). In controls, we observed increased β-catenin levels and increased cell-to-cell heterogeneity of b-catenin upon elimination of APC solely or in the context of activated KRAS, loss of p53, and reintroduction of a truncated APC protein frequently observed in CRCs. In each context, LRP6 silencing lowered β-catenin levels and suppressed their cell-to-cell heterogeneity. We obtained similar results using LRP6-interfering oligonucleotides (Saito-Diaz et al., 2018). In light of this heterogeneity, we speculate that the clones isolated by Chen and He may represent the skewed population of cells that are growing rapidly due to elevated β-catenin levels. Our results provide further support for our recent model for APC function and suggest that elevated levels of β-catenin in APC and LRP5/6 knockout clonal populations observed by Chen and He may simply be a consequence of clonal compensatory mechanisms.

Supplementary Material

1

ACKNOWLEDGMENTS

This work was funded by NIH grants R35GM122516 to E.L., R01GM122222 and R01GM121421 to Y.A., R01CA219189 to D.J.R, and R00DK103126 to C.A.T. and by grants from the Norris Cotton Cancer Center to Y.A.

Footnotes

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.devcel.2019.05.039.

DECLARATION OF INTERESTS

E.L. and D.J.R. are co-founders of StemSynergy Therapeutics Inc., a company that seeks to develop inhibitors of major signaling pathways (including the Wnt pathway) for the treatment of cancer.

REFERENCES

  1. Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns R, et al. (2018). Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clevers H, and Nusse R (2012). Wnt/b-catenin signaling and disease. Cell 149, 1192–1205. [DOI] [PubMed] [Google Scholar]
  3. El-Brolosy MA, and Stainier DYR (2017). Genetic compensation: A phenomenon in search of mechanisms. PLoS Genet. 13, e1006780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Krumins AM, and Gilman AG (2006). Targeted knockdown of G protein subunits selectively prevents receptor-mediated modulation of effectors and reveals complex changes in non-targeted signaling proteins. J. Biol. Chem 281, 10250–10262. [DOI] [PubMed] [Google Scholar]
  5. Liu Y, Mi Y, Mueller T, Kreibich S, Williams EG, Van Drogen A, Borel C, Frank M, Germain PL, Bludau I, et al. (2019). Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat. Biotechnol 37, 314–322. [DOI] [PubMed] [Google Scholar]
  6. Roig AI, Eskiocak U, Hight SK, Kim SB, Delgado O, Souza RF, Spechler SJ, Wright WE, and Shay JW (2010). Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology 138, 1012–1021. [DOI] [PubMed] [Google Scholar]
  7. Rossi A, Kontarakis Z, Gerri C, Nolte H, Hölper S, Krüger M, and Stainier DY (2015). Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 524, 230–233. [DOI] [PubMed] [Google Scholar]
  8. Saito-Diaz K, Benchabane H, Tiwari A, Tian A, Li B, Thompson JJ, Hyde AS, Sawyer LM, Jodoin JN, Santos E, et al. (2018). APC inhibits ligand-independent Wnt signaling by the clathrin endocytic pathway. Dev. Cell 44, 566–581.e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Thorne CA, Chen IW, Sanman LE, Cobb MH, Wu LF, and Altschuler SJ (2018). Enteroid monolayers reveal an autonomous WNT and BMP circuit controlling intestinal epithelial growth and organization. Dev. Cell 44, 624–633.e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Zhang L, Theodoropoulos PC, Eskiocak U, Wang W, Moon YA, Posner B, Williams NS, Wright WE, Kim SB, Nijhawan D, et al. (2016). Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Sci. Transl. Med 8, 361ra140. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES